Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Notifies Nanogen of Delisting Status on Minimum Bid Price

NEW YORK (GenomeWeb News) – The Nasdaq Stock Market has notified Nanogen that it may delist the company’s stock from the market due to failure to maintain a minimum bid price for 30 days, the company said Friday.
 
The notification has no effect on Nanogen’s stock currently, but if Nanogen’s shares do not trade at or above $1 per share for a period of 10 consecutive days in the next six months the firm will receive written notification from Nasdaq that its shares will be delisted.
 
The company’s stock has been trading under $1 steadily since mid-September and closed Friday at $.63 a share.
 
If Nanogen is delisted in May it may transfer to the Nasdaq Capital Market, at which time it will receive another 180 days to comply with the minimum bid rule.
 
Nanogen recently announced that it would shutter its microarray business, lay off around 20 percent of its staff, and realign the company behind its real-time PCR and point-of-care testing units.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.